Plus   Neg

Stock Alert: Intercept Pharmaceuticals Down 40%

Shares of Intercept Pharmaceuticals, Inc. (ICPT) are losing nearly 40% on Monday morning after the U.S. Food and Drug Administration declined to approve the drug maker's treatment for liver fibrosis.

ICPT is currently trading at $47.88, down $29.61 or 38.22%, on the Nasdaq.

In a Complete Response Letter, the FDA said that the predicted benefit of the treatment, obeticholic acid, or OCA, is uncertain and does not sufficiently outweigh the potential risks to support accelerated approval.

"The FDA recommends that Intercept submit additional post-interim analysis efficacy and safety data from the ongoing REGENERATE study in support of potential accelerated approval and that the long-term outcomes phase of the study should continue," the company said in a statement.

Intercept CEO Mark Pruzanski said, "We are disappointed to see the determination the Agency has reached based on an apparently incomplete review, and without having provided medical experts and patients the opportunity to be heard at the anticipated Adcom on the merits of OCA, which is a designated Breakthrough Therapy."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Department of Health and Human Services or HHS said it has secured most of the supply of COVID-19 drug remdesivir through September. The deal would allow American hospitals to purchase the antiviral drug in allocated amounts amid the spike in confirmed cases each day. HHS Secretary Alex Azar said, "President Trump has struck an amazing deal to ensure Americans have access to the first..." Novartis AG (NVS) agreed to pay $678 million to settle U.S. government charges it paid illegal kickbacks to doctors to induce them to prescribe its cardiovascular and diabetes drugs, the U.S. Department of Justice said in a statement. PG&E Corp. (PCG) said Wednesday that it has emerged from Chapter 11 bankruptcy protection, after implementing its financial restructuring plan that was previously approved by the U.S. Bankruptcy Court and state regulators.
Follow RTT